Skip to content

    Rainbow Child.

    RAINBOWGood
    Healthcare·14 Nov 2025
    Management Summary

    Rainbow Children's Medicare reported a soft Q2 FY26, primarily due to a lower-than-expected incidence of seasonal illnesses and an early festive season which compressed peak admission periods. Despite the transient impact on occupancy and PAT, the company continues its aggressive expansion, having integrated new acquisitions in Guwahati and Warangal. Management remains confident in long-term growth, backed by a strong project pipeline and a transition to a professional leadership structure with the appointment of a new Group CEO.

    Highlights

    7

    • Revenue for Q2 FY26 stood at ₹444.8 crores, representing a 6.5% YoY growth.

    • EBITDA reached ₹148.8 crores, a marginal increase of 1.2% YoY, with margins at 33.5%.

    • PAT witnessed a de-growth of 4.3% YoY, coming in at ₹75.6 crores.

    • Overall occupancy rate for the quarter was 52%, impacted by low seasonal illness incidence.

    • Company added 780 beds over the last two years through organic expansion and acquisitions.

    • Net cash position remains robust at ₹555.8 crores as of September 30, 2025.

    • Management targeting a 20% revenue CAGR over the next 2.5 to 3 years.

    Concerns

    1

    • Low incidence of seasonal illnesses

    What Changed1

    vs Q3 FY26

    Guidance items5 → 6 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹444.8 Cr+6.5%YoY
    2. 02EBITDA₹148.8 Cr+1.2%YoY
    3. 03EBITDA Margin33.5%
    4. 04PAT₹75.6 Cr-4.3%YoY
    5. 05Occupancy Rate52%

    Segment breakdown

    Mature Hospitals
    52% Occupancy-9% IP Volume Growth
    New Units
    41% Occupancy
    International Business
    ₹3 Cr Monthly Revenue
    IVF Services
    3.2% Revenue Mix40% Volume Growth
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Revenue CAGR
    20%
    		High
    Margin
    Base EBITDA Margin
    25%
    		High
    Capex
    H2 FY26 Capex
    ₹100 crores
    		High
    Capex
    Long-term Project Capex
    ₹600 crores
    		Medium
    Volume
    IVF Revenue Growth
    25%
    		Medium
    Market Share
    International Revenue Mix
    10%
    		Low

    Risks & concerns

    5
    RiskSeverity

    Low incidence of seasonal illnesses

    Directly led to lower patient volumes in general Paediatrics and PICU, impacting Q2 occupancy by 8-9%. — Management acknowledged

    high

    Construction delays in Gurugram

    Work stalled temporarily by the government due to dangerously high pollution levels. — Management acknowledged

    medium

    Geopolitical issues impacting International Business

    Bangladesh visa issues have significantly hampered patient flow from a key international market. — Both acknowledged

    medium

    Insurance transition in acquired units

    Temporary impact on revenue at Pratiksha and Prashanthi hospitals as insurance empanelment had to be redone post-acquisition. — Management acknowledged

    low

    Areas of Evasion(1)

    • Specific revenue contribution from newly acquired units (Pratiksha/Prashanthi) was given as a pre-acquisition range rather than exact current quarter contribution.

    Q&A highlights

    3

    “In years with no seasons, we see the impact clearly... occupancies are down by about 8% and revenue is down by around 10%–12%. If seasonality had been present, we would likely have delivered 16%–17% growth.”

    Explains the significant delta between reported growth and underlying potential, highlighting the business's sensitivity to seasonal disease cycles.

    asked by Rahul Jeewani, IIFL Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Seasonality Headwinds Impact Q2 Performance

    The quarter was characterized by 'softness' in operational performance, with revenue growing only 6.5% to ₹444.8 crores. Management attributed this to a low incidence of seasonal illnesses, which typically drive volumes in general Paediatrics and intensive care. Additionally, an early festive season (Ganesh Chaturthi and Dussehra) compressed the typical peak period for admissions, leading to a 52% occupancy rate compared to the 65-66% seen in the previous year.

    02

    Aggressive Capacity Expansion Phase Concludes

    Rainbow has added 780 beds over the past two years through a mix of greenfield expansions and strategic acquisitions. With the upcoming commencement of the Electronic City (~90 beds) and Hennur (~60 beds) facilities in Bengaluru, the company will conclude its current high-bed addition phase. This massive 47% increase in capacity from a low base forms the foundation for management's 20% CAGR revenue target over the next three years.

    03

    Strategic Entry into the Northeast Market

    The acquisition of Pratiksha hospital in Guwahati marks Rainbow's strategic entry into the Northeast region. Integration is complete, and the company is already scaling specialty services like road transport for critically sick children and adding pediatric neurology and nephrology. Management plans to build Guwahati as a regional hub before exploring greenfield opportunities in smaller cities like Silchar and Shillong.

    04

    Financial Resilience and Capex Roadmap

    Despite the soft quarter, the balance sheet remains robust with a net cash position of ₹555.8 crores. The company invested ₹260.6 crores in capex during Q2 and expects to spend another ₹100 crores in H2 FY26. Looking further ahead, a budget of ₹600 crores has been set for the Pune, Coimbatore, and Gurugram projects over the next three years, all of which are expected to be funded through internal accruals without debt.

    05

    Leadership Transition to Drive Next Growth Phase

    A significant milestone was the appointment of Mr. Abrarali Dalal as Group CEO, effective January 20, 2026. This move signals a transition from founder-led operations to a professional management structure. Dr. Ramesh Kancharla will remain as Chairman, focusing on strategy and alignment, while the CEO independently drives operations across the now significantly expanded multi-city network.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.